NCT00150202已完成3 期
Clinical Study Of EYE001 In Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 90
- 试验地点
- 15
- 主要终点
- Visual aquity change from the baseline to 54 weeks after the first treatment is expected to be similar to that seen in the Western studies.
研究概览
简要总结
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Wet AMD, Visual Acuity from 20/320 to 20/40
排除标准
- •Diabetic retinopathy, laser coagulation history
结局指标
主要结局
Visual aquity change from the baseline to 54 weeks after the first treatment is expected to be similar to that seen in the Western studies.
次要结局
- Safety profile of pegaptanib including side effects and lab test from the baseline to 54 weeks after the first treatment. Blood concentration of the drug from the baseline to 54 weeks after the irst treatment.
研究者
研究点 (15)
Loading locations...
相似试验
终止
1 期
Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in DiabeticsCystoid Macular EdemaNCT00346983Johns Hopkins University4
撤回
不适用
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic MyopiaMyopic Choroidal Neovascular MembraneNCT01218230L.V. Prasad Eye Institute
已完成
4 期
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular DegenerationRetinal Pigment Epithelial DetachmentChoroidal NeovascularizationNCT01628354University of Melbourne49
已完成
3 期
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic ConjunctivitisConjunctivitis, AllergicNCT02161146Allergan240
撤回
3 期
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic RetinopathyProliferative Diabetic RetinopathyNCT01589718Greater Houston Retina Research